The Change of the anti-VEGF Agent in the Treatment of Exceptionally Active Choroidal Neovascular Membrane in Age-Related Macular Degeneration
Authors:
M. Hovorka
Authors place of work:
Oční oddělení Masarykovy nemocnice, Ústí nad Labem, primářka MUDr. Ivana Liehneová
Published in the journal:
Čes. a slov. Oftal., 66, 2010, No. 3, p. 142-145
Category:
Case Report
Summary
Aim of this case report to present a case a male patient with age related macular degeneration succesfully treated by anti-VEGF substances different types.
The autor presents a case of 83 year old male with active choroidal neovasculare membrane. In this patient, the best corrected visual acuity (BCVA) of the left eye was 4/10 and the central retina thickness of the left eye was 320 μm. Activity of neovascular membrane was verified by OCT and FAG. Treatment was started with anti-VEGF Macugen. After 2 intravitreal injections of Macugen was state of retina worse. Treatment of the left eye was terminated according to recommendation in Information about drug Macugen. After that was started intravitreal applications of Lucentis. The state of retina was stabilizated after four injections of Lucentis. BCVA of the left eye was 4/20 and the central retina thickness was 130 μm. It happend after one year from beginning of therapy. Conclusions: Dosing of anti-VEGF substances results from clinical trials is suitable for treatment majority of patients with choroidal neovascular membrane. Change of anti-VEGF substance is necessary for stabilisation of state on retina in some cases.
Key words:
age related macular degeneration, anti-VEGF, Macugen, Lucentis
Zdroje
1. Automatický informační systém léčivých prostředků (AISLP) Souhrn informací o přípravku Macugen
2. Dubská Z.: Problematika věkem podmíněné makulární degenerace a současné možnosti její léčby se zaměřením na biologickou terapii.Klin. Farmakol. Farm., 2009; 23(3): 125–137.
3. Ferrara N., Gerber H.P., Le Courter J.: The biology of endotelial growth factor and its receptors. Nat. Med., 2003; 9: 669–676.
4. Gradoudas, E.S., Adami,A.P., Cunninghann, E.T. et al.: Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med., 2004; 351: 2805–2816.
5. Kolář P. a kol.: Věkem podmíněná makulární degenerace. Grada Publishing, 2008: 145.
6. Rosenfeld, J., Brown D.M., Heier J.S. et al.: Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 2006; 355: 1419–1431.
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2010 Číslo 3
Najčítanejšie v tomto čísle
- Treatment of the Choroidal Neovascular Membrane by Ranibizumab (Lucentis): A Case Report
- Epidemiology of the Age-Related Macular Degeneration
- The Change of the anti-VEGF Agent in the Treatment of Exceptionally Active Choroidal Neovascular Membrane in Age-Related Macular Degeneration
- Combined Therapy in the Exsudative Age-Related Macular Degeneration (Photodynamic Therapy and Intravitreally-Applied Ranibizumab)